---
title: "Pricing a weight-loss subscription patients keep for a year"
description: "Month-one margin is the wrong metric. How the strongest Cuvo brands structure intro pricing, refill cadence, and plan tiers to hold retention past month six."
canonical: "https://cuvo.co/blog/pricing-telehealth-subscriptions"
last-updated: "Jun 10, 2026"
---
# Pricing a weight-loss subscription patients keep for a year

By Priya Raman, Director of Partner Growth. Published Jun 10, 2026. Growth.

Month-one margin is the metric that flatters a weight-loss subscription and tells you almost nothing about it. A patient acquired at a cost, discounted into a first fill, and gone by month three is a different business than the same patient held through a full titration and into maintenance. This guide walks through how to structure intro pricing, refill cadence, and plan tiers so the economics reward retention past month six, where published persistence research says the real drop-off happens.

A weight-loss subscription looks profitable on the first invoice and reveals almost nothing there. The first month carries the full weight of acquisition cost, usually an intro discount, and a first medication fill, so the number an operator reads in month one is shaped mostly by how much was spent to win the patient and how much was given away to start them. The business is decided later, in whether the patient reaches maintenance and stays on treatment. Pricing a subscription patients keep for a year means designing every lever, the intro offer, the refill cadence, and the plan tiers, around that later question rather than the first one.

## 01. Why month-one margin is the wrong number to optimize

Three things distort month-one margin. Acquisition cost lands entirely in the first period, so a patient who churns after one fill can look like a small profit or a large loss depending only on how the accounting spreads that cost. Intro discounts, common across the category, mean the first fill is often sold below the standing price, so month one understates what a retained patient is worth. And the first fill is the lowest-commitment moment in the entire relationship: the patient has spent the least, felt the least benefit, and is the most likely to stop. Optimizing the price of that moment for margin can suppress the very start rate that feeds every later month.

The durable metric is contribution across the treatment journey: what a patient pays, minus wholesale medication cost and platform cost, summed across the months they actually stay. That number rewards retention, and retention is where weight-loss subscription economics live. A structure tuned to look healthy in month one, at the expense of the clinical support and payment mechanics that carry a patient through the fragile early months, is optimizing for the patients least likely to remain.

**Pricing for month one**
- Price the first fill to protect margin on a patient who may not reorder
- Treat acquisition cost as recovered inside the first invoice
- Read a healthy month-one P&L as a healthy business
- Miss that most discontinuation happens before maintenance
- Under-fund the check-ins, notifications, and dunning that hold months four through twelve

**Pricing for the year**
- Price the first fill to earn a second, a third, and a twelfth
- Spread acquisition cost across the treatment journey, not one invoice
- Judge the business on retention past month six
- Budget for the titration window, where side effects trigger pauses
- Fund the billing, refill, and outreach mechanics that keep patients on treatment

## 02. What persistence research says the pricing has to survive

The months that reward a brand are the maintenance months, after titration, when a patient is stable on a dose and reordering on a predictable cadence. Published data says a large share of patients never reach them. A 2026 analysis in the Journal of Managed Care & Specialty Pharmacy, drawing on Prime Therapeutics' claims database for 33,607 commercially insured adults without diabetes who started semaglutide or tirzepatide between January 2021 and June 2024, found one-year persistence improving over time but still far from complete. Semaglutide persistence rose from 33.2% in 2021 to 58.6% in the first half of 2024, while tirzepatide sat at 64.0% and 64.8% in 2023 and 2024. Persistence there means no gap longer than 60 days between fills across the year, so by that measure a third to two-thirds of patients did not stay continuously on treatment for twelve months, depending on the drug and the cohort.

- 33-65% One-year GLP-1 persistence, by drug and cohort (Prime Therapeutics claims analysis of 33,607 initiators, JMCP, March 2026)
- 20-40% Share of subscription churn that is involuntary, not chosen (Recurly, 2024, as summarized in 2026 industry analyses)
- ~70% Failed payments recoverable with combined dunning, retries, and card updater (Recurly, 2024; roughly 15% recover with no system in place)

The implication for pricing is direct. A structure that front-loads value into month one, and under-invests in the outreach, clinical support, and payment recovery that carry a patient through the early months, is optimizing for exactly the segment the research says is least likely to persist. Patients who discontinue early never reach the maintenance months that reward the brand. The pricing has to be built to survive that drop-off, not to look good before it happens.

## 03. Intro pricing: discounted month one versus flat

Public pricing pages in the category show two broad approaches. Some brands lead with a discounted first month to lower the barrier to starting: as of mid-2026, Noom's public pricing has listed an introductory first four-week supply well below its standing rate before moving patients onto a recurring plan billed in multi-week blocks. Others hold a flatter monthly price from the start, with GLP-1 programs from brands like Hims and Ro publicly listing compounded semaglutide and tirzepatide at standing monthly rates that vary by medication and dose. Neither is automatically right. A discounted month one improves the rate at which prospects start, which matters because a patient who never starts contributes nothing. But a steep discount also attracts patients who leave the moment the full price arrives, and the step from intro price to standing price is itself one of the most reliable churn events in any subscription.

- A discounted first month lowers the barrier to starting but sets a price anchor patients then expect to keep.
- A steep intro discount can attract patients who churn the moment the standing price lands.
- A flat price from day one earns less at the top of the funnel but selects for patients who accept the real cost.
- Whatever the intro, the step-up to full price is a churn event: it needs a reason to stay, not just a higher invoice.
- Model the intro against the whole journey, not the first invoice, so a discount that lifts the start rate is not misread as a loss.

## 04. Align billing cadence with clinical refill cadence

Weight-loss medication has a clinical cadence, and billing that ignores it creates friction. Both leading GLP-1 medications titrate. Per prescribing information, semaglutide steps up roughly every four weeks, from 0.25 mg through 0.5, 1.0, and 1.7 to a 2.4 mg maintenance dose over about sixteen weeks, and tirzepatide steps in 2.5 mg increments every four weeks toward a maintenance dose that can take twenty weeks to reach. During titration the dose, and often the prescription itself, changes monthly, and providers are checking tolerance, so monthly billing aligns naturally with monthly fills and monthly oversight. Once a patient reaches a stable maintenance dose, the clinical need to refill every month eases and a multi-month supply block becomes possible. That is where quarterly billing fits: it matches a stable dose to a larger, less frequent charge, and it cuts the number of times a payment can fail across a year.

**Billing cadence versus clinical refill cadence**

|  | Monthly billing | Quarterly billing |
| --- | --- | --- |
| Fits best | Titration, dose changing every 4 weeks | Maintenance, dose stable for months |
| Refill alignment | One charge, roughly one month of medication | One charge, a multi-month supply block |
| Cash flow | Smaller, more frequent charges | Larger upfront commitment per cycle |
| Failure exposure | ~12 payment events a year, 12 chances to fail | ~4 payment events a year, fewer failure points |
| Cancellation friction | Easy to stop between fills | Commitment spans a full supply block |

## 05. Plan-tier design: what belongs in each tier

Plan tiers let one brand serve patients who want different things without splitting the funnel. The base tier is usually medication only: the prescription, provider oversight, and fulfillment at the lowest headline price, which is what most price comparison happens on. Above it, tiers bundle the things that actually hold retention: structured check-ins, faster access to the care team, side-effect guidance through titration, and sometimes labs or coaching. The design question is not how many tiers but what belongs in each. Bundling support into a higher tier can fund the retention work that the base tier's price cannot cover, while a lean base tier stays competitive for patients shopping on monthly cost. The table below shows a common shape.

**A common three-tier structure**

| Tier | What it bundles | Who it fits |
| --- | --- | --- |
| Medication only | Prescription, provider oversight, fulfillment | Price-sensitive patients comparing on headline monthly cost |
| Medication plus support | Adds structured check-ins, messaging access, side-effect guidance | Patients who need help getting through titration |
| Full program | Adds labs, coaching or nutrition, priority support | Patients who want a managed program, not just a refill |

## 06. Where subscriptions leak, and which mechanics stop each leak

Subscriptions do not mostly leak through patients deciding the product is not worth it. They leak through mechanics. The largest hidden leak is involuntary churn: payments that fail because a card expired, hit a limit, or was reissued, from patients who never chose to leave. Industry analyses put involuntary churn at a large share of all subscription cancellations, and most of it is recoverable with the right systems. Weight-loss subscriptions add their own failure points. Side effects during titration prompt patients to pause, and a pause without a scheduled clinical touchpoint often hardens into a cancellation. A missed check-in can stall a refill, because a responsible program will not release the next fill without provider review. Each of these is addressable, but only if the platform running the subscription has the mechanic for it.

> **What Cuvo runs so pricing is the only variable you tune** Cuvo operates the subscription billing behind the brand: recurring charges, automated dunning and failed-payment recovery for involuntary churn, and refill authorization workflows that release the next fill once a provider clears it. Proactive notifications prompt patients before a refill lapses or a check-in comes due, and retention automation keeps outreach running through the titration months where pauses cluster. The operator sets the prices, the tiers, and the intro offer. Cuvo runs the infrastructure that collects on them and keeps patients on treatment.

## 07. How Cuvo's economics change the math you can run

Every pricing model above assumes a platform cost the operator can predict. Cuvo makes that cost a flat $25 per completed consult, with a 0% medication markup and wholesale pass-through on the drug itself, and no revenue share. That combination matters for pricing in a specific way: the platform charge is tied to a completed consult rather than a percentage of what the brand collects, so raising the retail price, adding a premium tier, or running an intro discount does not change what Cuvo charges. The spread between the price the operator sets and the wholesale medication cost plus the consult fee is the operator's to keep, and revenue settles directly to the operator's merchant account. Because there is no revenue share, the pricing decision stays entirely the operator's. Cuvo runs the billing, the clinical operations across all 50 states, and the fulfillment; the operator owns the price, the brand, and the marketing.

**Q: When should I discount the first month?**

A: Discount month one when the constraint is the start rate, not retention: a lower first fill lowers the barrier for prospects who would otherwise not begin, and a patient who never starts contributes nothing. The trade-off is that a steep discount attracts patients who leave when the standing price arrives, and the intro-to-standing step is a predictable churn point. If you discount, plan the step-up as a moment that needs a reason to stay, and judge the discount against contribution across the journey rather than the margin on the first invoice. On Cuvo, subscription billing handles the step-up and dunning automatically.

**Q: How does dose titration affect billing cadence?**

A: Both leading GLP-1 medications titrate in roughly four-week steps per prescribing information, so during the first few months the dose and prescription change monthly and providers are checking tolerance. Monthly billing aligns with that monthly fill-and-review rhythm. Once a patient is stable on a maintenance dose, a multi-month supply block becomes clinically reasonable, and quarterly billing then matches a stable dose to a larger, less frequent charge while cutting the number of payment events that can fail across a year. Cuvo's subscription billing supports monthly and multi-month cadences with automated dunning.

**Q: What happens when a patient's payment fails?**

A: A failed payment is usually involuntary churn, an expired or reissued card rather than a decision to cancel, and industry analysis suggests most of it is recoverable with the right system: smart retries, a card-updater service, and timed dunning reminders. On Cuvo, that recovery runs automatically behind the brand, so a failed charge triggers the retry and outreach sequence rather than silently dropping the patient off treatment.

**Q: Can patients change plans later?**

A: They should be able to. Letting a patient move between a medication-only tier and a bundled support tier turns a would-be cancellation into a plan change, which is a retention lever rather than a loss. Designing tiers so patients can step up when they want more help, or step down instead of leaving, keeps more of them on treatment across the year. On Cuvo, tiers run on the platform's subscription billing, with retention workflows that keep patients on treatment through a plan change.

**Keep reading**
- [The 5 best white label telehealth platforms in 2026](/blog/best-white-label-telehealth-platforms): How platforms differ on pricing and economics
- [Inside a compounded GLP-1 order](/blog/glp1-fulfillment-pipeline): The fulfillment cadence behind every refill
- [What a white-label telehealth platform costs in 2026](/blog/white-label-telehealth-platform-cost): The platform-side cost under the patient price
- [Cuvo pricing](/pricing): Flat per-consult pricing, 0% medication markup

*About this guide: This is a pricing strategy guide, not a forecast. Pricing outcomes depend on the operator's market, execution, acquisition costs, and competition, and nothing here is a guarantee of business performance. External figures are attributed to their published sources and were current as of July 2026; they describe the wider market, not any individual brand's results. Cuvo economics restate what cuvo.co publishes. Clinical decisions, including dosing and titration, always rest with licensed providers.*

Canonical page: https://cuvo.co/blog/pricing-telehealth-subscriptions